(Q33404763)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23228986%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

title

Acadesine for patients with relapsed/refractory chronic lymphocytic leukemia (CLL): a multicenter phase I/II study (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23228986%20AND%20SRC:MED&resulttype=core&format=json

multicenter clinical trial

20 February 2020

main subject

0 references

lymphocyte

0 references

acadesine

1 reference

chronic lymphocytic leukemia

ChEBI release 2020-05-28

1 reference

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23228986%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Maria José Terol

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23228986%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Vincent Levy

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23228986%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Jaime Pérez de Oteyza

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23228986%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Pierre Zachee

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23228986%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

author name string

Eric Van Den Neste

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23228986%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Bruno Cazin

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23228986%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Ann Janssens

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23228986%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Andrew Saunders

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23228986%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Mercè de Frias

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23228986%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Clara Campàs

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23228986%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

publication date

11 December 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23228986%20AND%20SRC:MED&resulttype=core&format=json

Cancer Chemotherapy and Pharmacology

20 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23228986%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

volume

71

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23228986%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23228986%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

page(s)

581-591

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23228986%20AND%20SRC:MED&resulttype=core&format=json

Creative Commons Attribution 2.0 Generic

20 February 2020

copyright license

start time

11 December 2012

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3579463

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3579463

Chronic lymphocytic leukemia: planning for an aging population

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3579463

TP53 mutation and survival in chronic lymphocytic leukemia

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3579463

AICAR induces apoptosis independently of AMPK and p53 through up-regulation of the BH3-only proteins BIM and NOXA in chronic lymphocytic leukemia cells.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3579463

Biologic and clinical significance of molecular profiling in Chronic Lymphocytic Leukemia

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3579463

AICA-riboside (acadesine), an activator of AMP-activated protein kinase with potential for application in hematologic malignancies

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3579463

Molecular and cellular mechanisms of CLL: novel therapeutic approaches.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3579463

The immunodeficiency of chronic lymphocytic leukaemia

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3579463

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3579463

Activation of adenosine monophosphate activated protein kinase inhibits growth of multiple myeloma cells

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3579463

Mutation of p53 and consecutive selective drug resistance in B-CLL occurs as a consequence of prior DNA-damaging chemotherapy

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3579463

Genomic aberrations and survival in chronic lymphocytic leukemia

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3579463

Acadesine (AICA-riboside): disposition and metabolism of an adenosine-regulating agent

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3579463

Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia.

21 June 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2033-5

Acadesine activates AMPK and induces apoptosis in B-cell chronic lymphocytic leukemia cells but not in T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2033-5

Acadesine: a new drug that may improve myocardial protection in coronary artery bypass grafting. Results of the first international multicenter study. Multinational Acadesine Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2033-5

Post-reperfusion myocardial infarction: long-term survival improvement using adenosine regulation with acadesine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2033-5

Chronic lymphocytic leukaemia

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23228986

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Acadesine, an adenosine-regulating agent with the potential for widespread indications

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23228986

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S00280-012-2033-5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23228986%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

20 February 2020

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23228986%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

PubMed publication ID

23228986

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23228986%20AND%20SRC:MED&resulttype=core&format=json